CLINICAL TRIAL SUMMARY

MDACC Study No:2005-0461 (clinicaltrials.gov NCT No: NCT00294632)
Title:A Study of Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma and Diffuse Large B-cell Non-Hodgkin's Lymphoma, transformed large cell lymphoma, and/or Grade 3 follicular lymphoma (follicular cleaved large cell lymphoma or follicular non-cleaved large cell lymphoma (RV-LYM-PI-0056)
Principal Investigator:Michael Wang
Treatment Agent:Lenalidomide; Rituximab
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of the drug lenalidomide (Revlimid, lenalidomide) that can be given with
RituxanŽ (rituximab) in the treatment of relapsed mantle cell lymphoma. The
safety and effectiveness of this combination treatment will also be studied in
both mantle cell lymphoma and diffuse large B-cell non-Hodgkin's lymphoma,
transformed large cell lymphoma, and/or Grade 3 follicular lymphoma (follicular
cleaved large cell lymphoma or follicular non-cleaved large cell lymphoma).

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I/Phase II
Treatment Agents:Lenalidomide
Rituximab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:No hospitalization is needed for protocol treatment purposes.
Supported By:N/A
Return Visit:Day 1, Day 8, Day 15, and 21 after starting therapy during the 1st cycle; every
2 weeks cycles 2 to 3; every 4 weeks after the third cycle of therapy until
disease progression is documented or study drug is discontinued for another
reason.
Home Care:Lenalidomide is in pill form and therefore could be taken orally at home.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Wang
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults